SNPX - Alzheimer's drug developer Synaptogenyx up 26% in afternoon trading

digicomphoto/iStock via Getty Images Synaptogenyx (SNPX), which has Bryostatin-1 in phase 2b for Alzheimer's disease, is up 26% in afternoon trading. After the closing bell yesterday, a piece from Seeking Alpha contributor DeepValuePlay called the company "the next big thing in Alzheimer's." Interim data from a phase 2b trial is expected in the 1H 2022, though DeepValuePlay says it might come before then. The author says trend analyses from a prior phase showed a significant positive slope of improvement for the treatment groups...that was significantly greater than for the placebo group." Synaptogenyx will receive a grant from the NIH to conduct a third phase 2 trial which will last longer (six months compared to 13 weeks previously) and focus on a moderate Alzheimer's population, which DeepValuePlay showed improvement in prior studies.

For further details see:

Alzheimer's drug developer Synaptogenyx up 26% in afternoon trading